Sodium Glucose Co-transporter 2 Inhibitors Mediated Ketogenesis in Patients with Metabolic Syndrome: Clear Benefit or Anticipated Fear?

Overview

Journal Arch Med Sci Atheroscler Dis

Date 2019 Apr 10

PMID 30963130

Citations 1

Authors

Dimitrios Ioannis Patoulias

Affiliations

Soon will be listed here.

Citing Articles

Empagliflozin therapy and insulin resistance-associated disorders: effects and promises beyond a diabetic state.

Papaetis G Arch Med Sci Atheroscler Dis. 2021; 6:e57-e78.

PMID: 34027215 PMC: 8117073. DOI: 10.5114/amsad.2021.105314.

References

Berge R, Tronstad K, Berge K, Rost T, Wergedahl H, Gudbrandsen O . The metabolic syndrome and the hepatic fatty acid drainage hypothesis. Biochimie. 2005; 87(1):15-20. DOI: 10.1016/j.biochi.2004.11.011. View

Satapati S, Sunny N, Kucejova B, Fu X, He T, Mendez-Lucas A . Elevated TCA cycle function in the pathology of diet-induced hepatic insulin resistance and fatty liver. J Lipid Res. 2012; 53(6):1080-92. PMC: 3351815. DOI: 10.1194/jlr.M023382. View

Cotter D, Ercal B, Huang X, Leid J, dAvignon D, Graham M . Ketogenesis prevents diet-induced fatty liver injury and hyperglycemia. J Clin Invest. 2014; 124(12):5175-90. PMC: 4348980. DOI: 10.1172/JCI76388. View

Taylor S, Blau J, Rother K . SGLT2 Inhibitors May Predispose to Ketoacidosis. J Clin Endocrinol Metab. 2015; 100(8):2849-52. PMC: 4525004. DOI: 10.1210/jc.2015-1884. View

Tie H, Shi R, Li Z, Zhang M, Zhang C, Wu Q . Risk of major adverse cardiovascular events in patients with metabolic syndrome after revascularization: A meta-analysis of eighteen cohorts with 18,457 patients. Metabolism. 2015; 64(10):1224-34. DOI: 10.1016/j.metabol.2015.06.019. View

Zinman B, Wanner C, Lachin J, Fitchett D, Bluhmki E, Hantel S . Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22):2117-28. DOI: 10.1056/NEJMoa1504720. View

Ferrannini E, Mark M, Mayoux E . CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetes Care. 2016; 39(7):1108-14. DOI: 10.2337/dc16-0330. View

Kruljac I, Cacic M, Cacic P, Ostojic V, Stefanovic M, Sikic A . Diabetic ketosis during hyperglycemic crisis is associated with decreased all-cause mortality in patients with type 2 diabetes mellitus. Endocrine. 2016; 55(1):139-143. DOI: 10.1007/s12020-016-1082-7. View

Gonzalez-Ortiz M, Mendez-Del Villar M, Martinez-Abundis E, Ramirez-Rodriguez A . Effect of dapagliflozin administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Minerva Endocrinol. 2016; 43(3):229-235. DOI: 10.23736/S0391-1977.16.02550-5. View

10.

Qiu H, Novikov A, Vallon V . Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives. Diabetes Metab Res Rev. 2017; 33(5). DOI: 10.1002/dmrr.2886. View

11.

Fadini G, Bonora B, Avogaro A . SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia. 2017; 60(8):1385-1389. DOI: 10.1007/s00125-017-4301-8. View

12.

Monami M, Nreu B, Zannoni S, Lualdi C, Mannucci E . Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials. Diabetes Res Clin Pract. 2017; 130:53-60. DOI: 10.1016/j.diabres.2017.04.017. View

13.

Neal B, Perkovic V, Mahaffey K, de Zeeuw D, Fulcher G, Erondu N . Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017; 377(7):644-657. DOI: 10.1056/NEJMoa1611925. View

14.

Ju S, Lee J, Kim D . Association of metabolic syndrome and its components with all-cause and cardiovascular mortality in the elderly: A meta-analysis of prospective cohort studies. Medicine (Baltimore). 2017; 96(45):e8491. PMC: 5690732. DOI: 10.1097/MD.0000000000008491. View

15.

Gershuni V, Yan S, Medici V . Nutritional Ketosis for Weight Management and Reversal of Metabolic Syndrome. Curr Nutr Rep. 2018; 7(3):97-106. PMC: 6472268. DOI: 10.1007/s13668-018-0235-0. View

16.

Davies M, DAlessio D, Fradkin J, Kernan W, Mathieu C, Mingrone G . Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018; 41(12):2669-2701. PMC: 6245208. DOI: 10.2337/dci18-0033. View

17.

Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A . Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018; 380(4):347-357. DOI: 10.1056/NEJMoa1812389. View

18.

Zelniker T, Wiviott S, Raz I, Im K, Goodrich E, Bonaca M . SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2018; 393(10166):31-39. DOI: 10.1016/S0140-6736(18)32590-X. View